GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (STU:I7G) » Definitions » Return-on-Tangible-Equity

Ipsen (STU:I7G) Return-on-Tangible-Equity : 273.11% (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Ipsen Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Ipsen's annualized net income for the quarter that ended in Dec. 2023 was €898 Mil. Ipsen's average shareholder tangible equity for the quarter that ended in Dec. 2023 was €329 Mil. Therefore, Ipsen's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was 273.11%.

The historical rank and industry rank for Ipsen's Return-on-Tangible-Equity or its related term are showing as below:

STU:I7G' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -60.04   Med: 66.67   Max: 719.16
Current: 105.26

During the past 13 years, Ipsen's highest Return-on-Tangible-Equity was 719.16%. The lowest was -60.04%. And the median was 66.67%.

STU:I7G's Return-on-Tangible-Equity is ranked better than
93.58% of 935 companies
in the Drug Manufacturers industry
Industry Median: 6.44 vs STU:I7G: 105.26

Ipsen Return-on-Tangible-Equity Historical Data

The historical data trend for Ipsen's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipsen Return-on-Tangible-Equity Chart

Ipsen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -60.04 719.16 111.59 67.54 77.59

Ipsen Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 99.20 84.07 43.98 57.66 273.11

Competitive Comparison of Ipsen's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ipsen's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipsen's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Ipsen's Return-on-Tangible-Equity falls into.



Ipsen Return-on-Tangible-Equity Calculation

Ipsen's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=644.4/( (1178.7+482.4 )/ 2 )
=644.4/830.55
=77.59 %

Ipsen's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=898.4/( (175.5+482.4)/ 2 )
=898.4/328.95
=273.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Ipsen  (STU:I7G) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Ipsen Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Ipsen's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Ipsen (STU:I7G) Business Description

Industry
Traded in Other Exchanges
Address
65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.

Ipsen (STU:I7G) Headlines

No Headlines